STI-3333

STI-3333, also referred to as T-VIVA-19, is a **protein-based SARS-CoV-2 vaccine candidate** developed by **Sorrento Therapeutics** for prevention of COVID-19. Public pipeline materials identify it as part of Sorrento's 2020 COVID-19 portfolio and describe it as a protein-based vaccine directed against the **SARS-CoV-2 spike protein**. Independent pipeline aggregators also list STI-3333 as a SARS-CoV-2 S protein inhibitor program in infectious and respiratory disease, but detailed public information on antigen design, formulation, adjuvant, clinical testing, and route of administration is limited. Based on the available evidence, STI-3333 appears to have remained an early-stage or preclinical asset and there is no clear evidence of later clinical advancement.

Brand names

T-VIVA-19T-VIVA19T-VIVA 19

Other names

targeted virus vaccine against COVID-19rS1-Fc vaccinerS-1-Fc vaccinerS 1-Fc vaccine